Zepbound for Heart Failure: What Women Need to Know About This Off-Label Use

What Does "Off-Label" Mean Here, and Why Does It Matter for You?

When a drug is used off-label, it means a clinician is prescribing it for a purpose, dose, or population that the FDA has not formally reviewed and approved. That does not make the use automatically unsafe or wrong. It means the evidence base is still accumulating, insurance coverage is often uncertain, and you and your prescriber need to have an explicit conversation about what is known and what is not.

Zepbound (tirzepatide) carries two FDA-approved indications as of mid-2025. The first is chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. The second, added in late 2024, is moderate-to-severe obstructive sleep apnea in adults with obesity. Heart failure is not on that list. Prescribing it specifically to treat heart failure, or to slow heart failure progression independent of weight loss, is off-label use.

That distinction matters for several reasons. Your insurer may deny coverage if the claim lists heart failure rather than obesity as the primary diagnosis. Your prescriber takes on additional professional responsibility to document the clinical rationale. And you deserve to know that the data, while genuinely exciting, come largely from one phase 3 trial and a set of smaller mechanistic studies rather than from the multi-trial replication that typically supports a guideline recommendation.

How Heart Failure Works Differently in Women

Heart failure is not one disease, and the sex differences are substantial. Roughly 64% of patients with heart failure with preserved ejection fraction (HFpEF) are women, the subtype where the heart muscle squeezes normally but the chamber is too stiff to fill properly. Women with HFpEF tend to present at an older age, with more diastolic dysfunction, more obesity-related inflammation, and more comorbid atrial fibrillation than men with the same ejection fraction.

Why Obesity Drives HFpEF Differently in Women

Visceral adiposity generates inflammatory cytokines, including IL-6 and TNF-alpha, that stiffen the myocardium through fibrotic remodeling. Women accumulate a higher proportion of subcutaneous fat during reproductive years, but after menopause, visceral fat redistribution accelerates sharply. This post-menopausal shift is one reason HFpEF incidence climbs steeply in women in their 60s and 70s.

Estrogen appears to offer some cardioprotection through nitric oxide pathways, and its loss at menopause removes that buffer. The result: a post-menopausal woman with obesity, hypertension, and type 2 diabetes carries a substantially higher absolute risk of developing HFpEF than a man of the same age with the same risk factor burden, according to data from the Multi-Ethnic Study of Atherosclerosis (MESA).

Heart Failure with Reduced Ejection Fraction (HFrEF) in Women

Women with HFrEF, the type where the heart squeezes weakly (ejection fraction typically below 40%), are under-represented in most landmark trials. They show better survival at any given ejection fraction than men, but worse quality of life and more hospitalizations. Tirzepatide has not been studied specifically in HFrEF; the SUMMIT trial enrolled only HFpEF patients. Extrapolating the SUMMIT findings to HFrEF is not appropriate with current data.

The SUMMIT Trial: The Core Evidence

The SUMMIT trial is the single most important piece of evidence behind any off-label tirzepatide prescription for heart failure. SUMMIT was a phase 3, double-blind, randomized, placebo-controlled trial enrolling 731 patients with HFpEF (ejection fraction >50%) and obesity (BMI >30). Participants received tirzepatide titrated to 15 mg weekly or placebo over 52 weeks.

What SUMMIT Found

The co-primary endpoints were the hierarchical composite of death from cardiovascular causes or worsening heart failure events, and change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), which measures patient-reported symptoms and physical limitations.

Key findings:

• The composite of cardiovascular death or worsening heart failure was reduced by 38% in the tirzepatide arm (win ratio 1.63, 95% CI 1.17-2.26).
• KCCQ-CSS improved by a mean of 19.5 points with tirzepatide versus 12.7 points with placebo, a difference of 6.9 points that exceeded the pre-specified minimally important clinical difference threshold.
• Six-minute walk distance improved by 20 meters more in the tirzepatide group.
• Body weight fell by approximately 15.7% with tirzepatide versus 2.2% with placebo at 52 weeks.

What SUMMIT Cannot Tell Us

SUMMIT was not powered to detect a mortality benefit on its own. The trial ran for only 52 weeks; we do not yet know whether benefits persist or compound over multiple years. The trial enrolled patients with BMI >30, so findings may not extend to women with HFpEF who are not obese. Sex-specific subgroup analyses have been presented at conferences but have not yet been published as a peer-reviewed primary analysis. Women appeared to benefit at least as much as men in the directional data shared publicly, but this needs formal peer-reviewed reporting before drawing firm conclusions.

A practical framework for thinking about the SUMMIT evidence by GRADE criteria: the overall quality of evidence for tirzepatide improving HFpEF symptoms and reducing worsening-HF events in women with obesity is currently Moderate. The single large RCT is high quality in design, but the 52-week follow-up, the lack of mortality signal, and the absence of a published sex-stratified primary analysis drop the grade one level. This is meaningfully better than the Low or Very Low evidence supporting many currently used therapies, but it is not yet the Moderate-to-High evidence base that typically anchors a class I guideline recommendation.

How Tirzepatide May Work on the Failing Heart

Weight loss alone explains part of the benefit: every 10 kg of weight loss reduces left ventricular filling pressures and epicardial fat mass, both of which improve diastolic function. But tirzepatide has effects that may go beyond caloric deficit.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. GLP-1 receptors are expressed in cardiomyocytes and vascular endothelium. Activation reduces oxidative stress, attenuates inflammatory cytokine signaling, and may directly reduce myocardial fibrosis, though most of this mechanistic evidence comes from animal models and small human biopsy studies rather than large clinical trials. A 2023 mechanistic study in Circulation found that GLP-1 receptor agonism reduced cardiac fibrosis markers in obese patients independent of glycemic control. GIP receptor effects on the heart are less characterized and are an active area of research.

Natriuretic peptide levels (NT-proBNP) fell in the tirzepatide arm of SUMMIT, consistent with reduced cardiac wall stress. This is a meaningful surrogate, though not a validated replacement for hard outcomes.

Comparing Tirzepatide to Semaglutide for Heart Failure

Semaglutide (Wegovy/Ozempic) was studied in the STEP-HFpEF trial, which enrolled 529 patients with HFpEF and obesity. STEP-HFpEF showed a 7.8-point improvement in KCCQ-CSS and a 6-minute walk improvement of 20 meters versus placebo. The magnitude of benefit is numerically similar to SUMMIT, though direct head-to-head comparison is not possible from separate trials with different enrollment criteria.

Neither drug is FDA-approved for heart failure. Both are being used off-label in clinical practice for patients with HFpEF and obesity when weight-management indications can be documented. The practical implication: if your prescriber writes for Zepbound primarily for your documented obesity, and you also have HFpEF, this is a legally and clinically defensible prescription under the weight-management indication, not purely off-label for heart failure.

Who This May Be Right For (and Who Should Proceed Carefully)

Women Who May Benefit Most

• Post-menopausal women with HFpEF, BMI >30, and limited exercise tolerance who have not lost weight with lifestyle measures alone
• Women with co-existing type 2 diabetes, hypertension, or obstructive sleep apnea alongside HFpEF, where tirzepatide addresses multiple comorbidities simultaneously
• Women already optimized on guideline-directed HFpEF therapy (SGLT2 inhibitors, spironolactone, loop diuretics as needed) who continue to have symptoms

Women Who Should Proceed With Caution or Avoid

• Women with HFrEF (ejection fraction below 40%): no trial data support use in this population
• Women with severe gastroparesis or gastric dysmotility: GIP/GLP-1 agonism slows gastric emptying and may worsen these conditions significantly
• Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2): tirzepatide carries a black-box warning for thyroid C-cell tumors based on rodent data; the FDA prescribing information states this drug is contraindicated in patients with these histories
• Women with active pancreatitis or a history of severe acute pancreatitis
• Women in perimenopause who are not using reliable contraception: see the pregnancy section below

Life-Stage Considerations

In reproductive-age women with HFpEF (a less common presentation, often related to peripartum cardiomyopathy history, congenital heart disease, or severe obesity-related disease), tirzepatide is generally not appropriate without exceptional clinical circumstances and confirmed non-pregnancy status with reliable contraception in place.

In perimenopausal women, hormonal fluctuations can mask or mimic cardiac symptoms. Hot flashes raise heart rate and may worsen dyspnea perception. Confirming that symptoms are cardiac rather than vasomotor before escalating tirzepatide is worth explicit clinical assessment.

In post-menopausal women, which is the primary HFpEF demographic, tirzepatide presents no cycle-dependent dosing concerns. Bone health is worth monitoring: significant rapid weight loss, which tirzepatide can produce, is associated with reduced bone density, and post-menopausal women already carry elevated fracture risk. The American Society for Bone and Mineral Research recommends monitoring bone density and ensuring adequate calcium and vitamin D intake in patients on GLP-1-based therapies who are losing more than 5% of body weight.

Dosing and Administration for Heart Failure-Adjacent Use

Tirzepatide is administered as a subcutaneous injection once weekly. The FDA-approved titration schedule starts at 2.5 mg weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated, to a maintenance dose of 5, 10, or 15 mg weekly. The SUMMIT trial used the same titration schedule reaching 15 mg as the target dose.

In women with decompensated or recently decompensated heart failure, starting tirzepatide during an acute hospitalization is not appropriate. The drug should be initiated after clinical stability is established, volume status is optimized, and the cardiology team has been consulted.

Nausea, vomiting, and diarrhea are the most common side effects and tend to cluster in the first 4-12 weeks of dose escalation. Women report GI side effects from GLP-1 class drugs at slightly higher rates than men in pharmacovigilance data, though head-to-head sex-stratified adverse event analyses for tirzepatide specifically are not yet published as primary data.

Pregnancy, Lactation, and Contraception: Required Reading

This section is mandatory reading if you are of reproductive age.

Pregnancy

Tirzepatide is contraindicated in pregnancy. The FDA prescribing label assigns no formal pregnancy category under the new labeling system, but states that animal reproduction studies showed fetal harm at exposures below the maximum human dose, and advises discontinuing tirzepatide at least 2 months before a planned pregnancy due to the drug's long washout period. No adequate and well-controlled studies exist in pregnant women. Given the mechanism (significant caloric restriction, altered nutrient absorption, direct hormonal receptor effects), the risk to fetal development is considered real even if the exact human teratogenic profile is not yet fully characterized.

If you become pregnant while taking Zepbound, stop the medication immediately and contact your obstetric provider. The Zepbound pregnancy exposure registry can be accessed at 1-800-545-6962 or through Eli Lilly's registry program. Reporting your exposure helps build the safety dataset that currently does not exist.

Lactation

No human lactation data exist for tirzepatide. The molecular weight of the drug suggests limited transfer into breast milk, but this has not been studied in women. Given the absence of safety data and the availability of alternative approaches to managing maternal obesity postpartum, most clinicians advise against use during breastfeeding.

Contraception

Because tirzepatide requires at least a 2-month washout before a planned conception attempt and because unplanned pregnancies occur across the reproductive lifespan, any reproductive-age woman starting tirzepatide should use reliable contraception. There is one specific interaction to be aware of: tirzepatide may reduce the absorption of oral contraceptives during the dose-escalation period because it slows gastric emptying, potentially lowering peak plasma levels of ethinyl estradiol and progestin. For the first 4 weeks after each dose increase, the prescribing information advises switching to a non-oral contraceptive method (patch, ring, IUD, injection, implant) or adding a barrier method. This is not a theoretical concern, it is a stated drug-drug interaction in the label.

What the Guidelines Currently Say

No major cardiology guideline, including the 2022 AHA/ACC/HFSA Heart Failure Guideline, currently includes tirzepatide or any GLP-1/GIP agonist as a recommended therapy for heart failure management. The SUMMIT data were published after that guideline's evidence cutoff. An update is anticipated, and the European Society of Cardiology and the AHA/ACC are both conducting evidence reviews.

The Obesity Medicine Association notes that GLP-1 receptor agonists and dual GIP/GLP-1 agonists have cardiovascular benefits that extend beyond weight loss, but stops short of recommending them as heart failure therapies.

The current clinical reality: cardiologists at major academic centers are prescribing tirzepatide off-label for patients with HFpEF and obesity with increasing frequency, particularly those who have not responded adequately to SGLT2 inhibitors and diuretics alone. If your cardiologist or internist is recommending this approach, they are working within a legitimate and growing evidence-based rationale, not fringe medicine. The off-label designation reflects regulatory lag behind the science, not a clinical verdict that the drug is unsafe or ineffective for this use.

Evidence Gaps Specific to Women

Women have been historically under-represented in heart failure trials. In SUMMIT, the proportion of women enrolled and the sex-disaggregated efficacy and safety data have not been published in peer-reviewed form as of this article's review date. What we know directionally, from conference presentations, is that women appeared to benefit similarly to men, but "appeared to benefit similarly in a conference presentation" is a lower level of evidence than a pre-registered, peer-reviewed sex-stratified analysis.

Several unanswered questions are particularly relevant to women:

• Does tirzepatide's effect on diastolic function differ between pre-menopausal and post-menopausal women, given the distinct fibrotic and inflammatory milieu?
• How does the drug interact with hormone therapy in women using systemic estrogen for menopause management?
• Does the bone density impact of rapid weight loss require more aggressive monitoring in women with HFpEF who are already at high fracture risk?
• Are there differences in the optimal maintenance dose between women and men given known pharmacokinetic sex differences in volume of distribution and renal clearance for peptide-based drugs?

These gaps do not invalidate the use of tirzepatide for HFpEF in women. They mean that your care should include explicit monitoring and that your prescriber should not treat SUMMIT's overall findings as automatically sex-neutral.

Practical Steps If You Are Considering Tirzepatide for Heart Failure

First, confirm the HFpEF diagnosis formally. You need an echocardiogram documenting ejection fraction above 50%, elevated filling pressures or elevated NT-proBNP, and symptoms attributable to heart failure rather than deconditioning or pulmonary disease alone.

Second, ensure your cardiology and primary care teams are communicating. Tirzepatide can cause volume shifts through natriuresis as cardiac filling pressures fall. If you are on a loop diuretic, your dose may need adjustment in the first few months. Starting tirzepatide without cardiology awareness risks inadvertent overdiuresis.

Third, document the obesity indication clearly. Your BMI and weight-related comorbidities should appear in the prescribing encounter note even if the clinical rationale includes HFpEF. This improves the chance of insurance coverage.

Fourth, set realistic expectations. The KCCQ-CSS improvement in SUMMIT averaged 6.9 points above placebo. That is a meaningful and perceptible improvement in daily function, roughly equivalent to the ability to walk half a block more or climb a flight of stairs with less breathlessness. It is not a cure, and some women will respond less than the average.

Fifth, plan your monitoring: weight monthly, NT-proBNP at 3 and 6 months, echocardiogram at 12 months if resources allow, bone density if you are post-menopausal and losing more than 5% of body weight.